Ligand Pharmaceuticals Receives Authorisation from the FDA for Molluscum Contagiosum Gel

Ligand Pharmaceuticals’ Zelsuvmi dermatological gel to treat Molluscum contagiosum has received authorisation from the FDA.  

Molluscum contagiosum is a viral skin infection characterized by the development of small nodules on the skin. It is caused by the molluscum contagiosum virus, and managing the infection is crucial to inhibit transmission.  

The granted approval permits the medication’s utilization in both adults and infants above one year of age, with anticipated commercial availability in the United States during the latter part of 2024.  

The effectiveness of Zelsuvmi was shown in multiple late-stage studies where it was shown to be able to reduce the number of lesions when applied once per day.  

Todd, Davis, the executive officer of Ligand, stated, “We are proud of the team’s accomplishment, having completed the world’s largest clinical programme in molluscum to bring this first-in-class topical medication to FDA approval.”  

Davis went on to add, “Paediatricians, dermatologists and caregivers have long sought a convenient approach to treat this highly contagious skin infection.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.